Pediococcus acidilactici pA1c® improves the beneficial effects of metformin treatment in type 2 diabetes by controlling glycaemia and modulating intestinal microbiota
Fecha
2023Autor
Versión
Acceso abierto / Sarbide irekia
Tipo
Artículo / Artikulua
Versión
Versión publicada / Argitaratu den bertsioa
Identificador del proyecto
AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PTQ2019-010384 Gobierno de Navarra//0011-1365-2020-000086
Impacto
|
10.3390/pharmaceutics15041203
Resumen
Type 2 diabetes (T2D) is a complex metabolic disease, which involves maintained hyperglycemia, mainly due to the development of an insulin resistance process. Metformin administration
is the most prescribed treatment for diabetic patients. In a previously published study, we demonstrated that Pediococcus acidilactici pA1c® (pA1c) protects from insulin resistance and body weight
gain in HFD-indu ...
[++]
Type 2 diabetes (T2D) is a complex metabolic disease, which involves maintained hyperglycemia, mainly due to the development of an insulin resistance process. Metformin administration
is the most prescribed treatment for diabetic patients. In a previously published study, we demonstrated that Pediococcus acidilactici pA1c® (pA1c) protects from insulin resistance and body weight
gain in HFD-induced diabetic mice. The present work aimed to evaluate the possible beneficial
impact of a 16-week administration of pA1c, metformin, or the combination of pA1c and metformin
in a T2D HFD-induced mice model. We found that the simultaneous administration of both products attenuated hyperglycemia, increased high-intensity insulin-positive areas in the pancreas and
HOMA-β, decreased HOMA-IR and also provided more beneficial effects than metformin treatment (regarding HOMA-IR, serum C-peptide level, liver steatosis or hepatic Fasn expression), and
pA1c treatment (regarding body weight or hepatic G6pase expression). The three treatments had a
significant impact on fecal microbiota and led to differential composition of commensal bacterial
populations. In conclusion, our findings suggest that P. acidilactici pA1c® administration improved
metformin beneficial effects as a T2D treatment, and it would be a valuable therapeutic strategy to
treat T2D. [--]
Materias
Pediococcus acidilactici,
Probiotic,
Metformin,
High-fat diet,
Diabetes,
Glycaemia,
Intestinal microbiota
Editor
MDPI
Publicado en
Pharmaceutics 2023, 15, 1203
Departamento
Universidad Pública de Navarra. Departamento de Ciencias de la Salud /
Nafarroako Unibertsitate Publikoa. Osasun Zientziak Saila
Versión del editor
Entidades Financiadoras
This research was funded by a grant from the Government of Navarre (Ayudas para la realización de proyectos de I+D 2020) (Reference: 0011-1365-2020-000086). M.C.O. was funded by a postdoctoral fellowship “Ayudas para la Recualificación del Sistema Universitario Español para 2021–2023, UPNA, Modalidad Margarita Salas”, funded by the European Union—NextGenerationEU. M.O. was supported by Torres-Quevedo grants from the Spanish Ministry of Science and innovation (Ayudas para contratos Torres Quevedo PTQ2019-010384/AEI/10.13039/501100011033)